Inaishi, Jun
Saisho, Yoshifumi
Watanabe, Yuusuke
Tsuchiya, Tami
Sasaki, Hironobu
Masaoka, Tatsuhiro
Itoh, Hiroshi
Article History
Received: 2 November 2021
Accepted: 3 January 2022
First Online: 11 January 2022
Declarations
:
: This study was carried out with the approval of the Keio University Institutional Review Board for Clinical Research (20140298, approval date: Dec 12, 2014), and registered as trial numbers UMIN000016390 and jRCTs031180320. Before enrollment, all participants provided written informed consent to the investigators.
: Not applicable.
: J.I., Y.W., T.T. and H.S. have no conflict of interest to declare. Y.S. reports honoraria from Sumitomo Dainippon Pharma Co. T.M. reports honoraria from AstraZeneca K.K. and Otsuka Pharmaceutical. H.I. reports grants and honoraria from Shionogi & Co., Nippon Boehringer Ingelheim, MSD K.K., Daiichi Sankyo, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corp., Taisho Toyama Pharmaceutical, and Shionogi & Co.; grants from Astellas Pharma, Sumitomo Dainippon Pharma Co., Teijin Pharma, Kyowa Hakko Kirin, Mochida Pharmaceutical Co., Chugai Pharmaceutical, Ono Pharmaceutical Co., and Eli Lilly and Company, Japan K.K.; and personal fees from SBI Pharmaceuticals Co. and Nipro Corp.